Trial Profile
Pharmacokinetic Study of YM150 - The Verification ot the Bioequivalence Between YM150 Formulation-A and YM150 Formulation-B.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 May 2010
Price :
$35
*
At a glance
- Drugs Darexaban (Primary)
- Indications Acute coronary syndromes; Thromboembolism; Venous thrombosis
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 21 May 2010 New trial record